{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:34:43Z","timestamp":1792532083169,"version":"4.5.0"},"reference-count":39,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","award":["GETAID\u20102021\u201002"],"award-info":[{"award-number":["GETAID\u20102021\u201002"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aim<\/jats:title>\n                    <jats:p>We conducted a prospective study to evaluate the persistence, efficacy, pharmacokinetics, and safety of subcutaneous VDZ (SC\u2010VDZ) after switching from the intravenous (IV) route.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients with ulcerative colitis (UC) or Crohn's disease (CD) in clinical remission who switched from IV\u2010VDZ to SC\u2010VDZ between 2022 and 2024 were included in this multicentric prospective French national cohort study. Primary endpoint was SC\u2010VDZ persistence at Week 52. Patients who had a disease\u2010related surgery, repeated or prolonged (&gt;\u200914\u2009days) steroid courses, and those who were lost to follow\u2010up were considered non\u2010persistent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 337 patients analysed, 246 (73%) had UC and 91 (27%) CD; 214 (64%) were on a standard IV\u2010VDZ regimen. At Week 52, SC\u2010VDZ persistence was 84% [95% confidence interval: 80\u201388], with no significant difference between diseases (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.36). During the study period, 32 patients (10%) had a dose increase of SC\u2010VDZ (either to 216\u2009mg weekly or to 108\u2009mg 2\u2010weekly), including 17 (53%) who had been on a standard IV\u2010VDZ regimen, and five (16%) eventually stopped VDZ due to persistent loss\u2010of\u2010response despite dose increase. Twelve out of 16 patients were successfully switched back to IV\u2010VDZ. Vedolizumab drug levels were similar between persistent and non\u2010persistent patients throughout the study period. A total of 183 patients (54%) reported at least one AE, most frequently injection\u2010site reactions (20%) and infections (17%), leading to SC\u2010VDZ discontinuation in 25 patients (7%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this multicentric cohort, the persistence at 1\u2009year from switch to SC\u2010VDZ in IBD patients was 84%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.70986","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:35:06Z","timestamp":1790570106000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Persistence, Safety and Pharmacokinetics of Vedolizumab After Switching to the Subcutaneous Route in a Prospective French National Cohort Study"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5158-2321","authenticated-orcid":false,"given":"Marianne","family":"Hup\u00e9","sequence":"first","affiliation":[{"name":"Univ. Grenoble Alpes\/Hepato\u2010Gastroenterology and Digestive Oncology Department CHU Grenoble Alpes\/Institute for Advanced Biosciences, CNRS UMR 5309\u2010INSERM U1209  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Mathieu","sequence":"additional","affiliation":[{"name":"IBD Private Institute  Echirolles France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Amiot","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology University Hospital of Bic\u00eatre, Assistance Publique\u2010H\u00f4pitaux de Paris, Universite Paris Salcay, CESP INSERM UMR 1018  Le Kremlin Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3596-9893","authenticated-orcid":false,"given":"Philippe","family":"Seksik","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology CRSA, Sorbonne Universit\u00e9, INSERM UMRS\u2010938, Gut, Liver &amp; Microbiome Research (GLIMMER) FHU, APHP, H\u00f4pital Saint\u2010Antoine  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Charkaoui","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology CHU Dijon  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Gilletta\u2010de\u2010Saint\u2010Joseph","sequence":"additional","affiliation":[{"name":"Pancreatology and Gastroenterology Department CHU Toulouse Rangueil  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4903-3535","authenticated-orcid":false,"given":"Arnaud","family":"Bourreille","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, Institut des Maladies de l\u2019Appareil Digestif, CHU de Nantes, CIC Inserm 1413  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Serrero","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology APHM, H\u00f4pital Nord  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Bouhnik","sequence":"additional","affiliation":[{"name":"Institut des MICI, Groupe Hospitalier Priv\u00e9 Ambroise Par\u00e9 \u2013 Hartmann  Neuilly\u2010sur\u2010Seine France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nachury","sequence":"additional","affiliation":[{"name":"Univ. Lille, Inserm, CHU Lille, U1286 \u2010 INFINITE \u2010 Institute for Translational Research in Inflammation  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-4878","authenticated-orcid":false,"given":"Xavier","family":"Roblin","sequence":"additional","affiliation":[{"name":"Gastroenteroly University Hospital of Saint\u2010Etienne  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2088-1442","authenticated-orcid":false,"given":"St\u00e9phane","family":"Nancey","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9pato\u2010Gastroent\u00e9rologie H\u00f4pital de Lyon, CHU de Lyon, Universit\u00e9 Lyon 1 et Inserm U1111\u2010CIRI  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered","family":"Abitbol","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie H\u00f4pital Cochin AP\u2010HP; Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Marc","family":"Gornet","sequence":"additional","affiliation":[{"name":"Service de Gastroent\u00e9rologie et d'oncologie digestive H\u00f4pital Saint\u2010Louis  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Montuclard","sequence":"additional","affiliation":[{"name":"Service de Gastro\u2010ent\u00e9rologie Centre Hospitalier de Valence  Valence France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5903-8834","authenticated-orcid":false,"given":"Xavier","family":"H\u00e9buterne","sequence":"additional","affiliation":[{"name":"Service de Gastro\u2010ent\u00e9rologie et Nutrition CHU de Nice et Universit\u00e9 C\u00f4te d\u2019Azur  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Paupard","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9pato\u2010Gastroent\u00e9rologie Centre Hospitalier Alexandra Lep\u00e8ve  Dunkerque France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9a","family":"Rouillon","sequence":"additional","affiliation":[{"name":"Service de Gastro\u2010ent\u00e9rologie et H\u00e9patologie CHU de Caen  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Kaassis","sequence":"additional","affiliation":[{"name":"Service d'h\u00e9pato\u2010gastro\u2010ent\u00e9rologie Centre Hospitalier Cholet  Cholet France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Andrau","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9pato\u2010gastro\u2010ent\u00e9rologie, Oncologie digestive et Addictologie Centre Hospitalier Tarbes\u2010Lourdes  Tarbes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Amil","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9pato\u2010gastro\u2010ent\u00e9rologie Centre Hospitalier D\u00e9partemental Vend\u00e9e  La Roche\u2010sur\u2010Yon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Baudrant","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Grenoble University Hospital  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin\u2010Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology CHRU Nancy, INSERM NGERE, Universit\u00e9 de Lorraine, F\u201054500 Vand\u0153uvre\u2010l\u00e8s\u2010Nancy  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8830-4273","authenticated-orcid":false,"given":"St\u00e9phane","family":"Paul","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, iBioThera, CHU Saint Etienne France. CIRI (Centre International de Recherche en Infectiologie), Universit\u00e9 Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon, Universit\u00e9 Jean Monnet de Saint\u2010Etienne, France. 4CIC1408, University Hospital of Saint\u2010Etienne  Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de recherche clinique Lariboisi\u00e8re St Louis\/H\u00f4pital F.Widal 200 rue du Faubourg Saint Denis 75010 Paris  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4753-6676","authenticated-orcid":false,"given":"David","family":"Laharie","sequence":"additional","affiliation":[{"name":"Service d'h\u00e9pato\u2010Gastroent\u00e9rologie, CMC Magellan CHU de Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(16)31711\u20101"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(16)32126\u20102"},{"key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease","volume":"369","author":"Sandborn W. J.","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"369","author":"Feagan B. G.","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus Adalimumab for Moderate\u2010to\u2010Severe Ulcerative Colitis","volume":"381","author":"Sands B. E.","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The Safety of Vedolizumab for Ulcerative Colitis and Crohn's Disease","volume":"66","author":"Colombel J. F.","year":"2016","journal-title":"Gut"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271\u2010014\u20100075\u2010y"},{"key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/ibd\/izac119","article-title":"Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study","volume":"29","author":"Buisson A.","year":"2023","journal-title":"Inflammatory Bowel Diseases"},{"key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"e14341","DOI":"10.1111\/ijcp.14341","article-title":"Comparing Cost of Intravenous Infusion and Subcutaneous Biologics in COVID\u201019 Pandemic Care Pathways for Rheumatoid Arthritis and Inflammatory Bowel Disease: A Brief UK Stakeholder Survey","volume":"75","author":"Heald A.","year":"2021","journal-title":"International Journal of Clinical Practice"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2023.2285229"},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial","volume":"16","author":"Vermeire S.","year":"2022","journal-title":"Journal of Crohn's & Colitis"},{"key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis","volume":"158","author":"Sandborn W. J.","year":"2020","journal-title":"Gastroenterology"},{"key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"452","DOI":"10.15403\/jgld-5084","article-title":"Effectiveness and Safety of Switching From Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission","volume":"32","author":"Parisio L.","year":"2023","journal-title":"Journal of Gastrointestinal and Liver Diseases"},{"key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1007\/s10620-024-08631-2","article-title":"Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study","volume":"69","author":"Principi M.","year":"2024","journal-title":"Digestive Diseases and Sciences"},{"key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/medicina60020296","article-title":"Remission Is Maintained After Switch From Dose\u2010Optimised Intravenous Treatment to Subcutaneous Treatment With Vedolizumab in Inflammatory Bowel Disease","volume":"60","author":"Pintar \u0160.","year":"2024","journal-title":"Medicina"},{"key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/ecco-jcc\/jjab224","article-title":"Transitioning From Intravenous to Subcutaneous Vedolizumab in Patients With Inflammatory Bowel Disease [TRAVELESS]","volume":"16","author":"Ventress E.","year":"2022","journal-title":"Journal of Crohn's & Colitis"},{"key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/apt.16927","article-title":"Real\u2010World Data on Switching From Intravenous to Subcutaneous Vedolizumab Treatment in Patients With Inflammatory Bowel Disease","volume":"55","author":"Bergqvist V.","year":"2022","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"e14283","DOI":"10.1111\/eci.14283","article-title":"An International Multicentre Study of SwiTching From Intravenous to Subcutaneous inflixiMab and vEdolizumab in Inflammatory Bowel Diseases: The TIME Study","volume":"54","author":"D'Amico F.","year":"2024","journal-title":"European Journal of Clinical Investigation"},{"key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.dld.2023.07.011","article-title":"Switching From VEDOlizumab Intravenous to Subcutaneous Formulation in Ulcerative Colitis Patients in Clinical Remission: The SVEDO Study, an IG\u2010IBD Study","volume":"56","author":"Ribaldone D. G.","year":"2024","journal-title":"Digestive and Liver Disease"},{"key":"e_1_2_11_21_1","doi-asserted-by":"crossref","first-page":"502379","DOI":"10.1016\/j.gastrohep.2025.502379","article-title":"Alta persistencia al a\u00f1o de vedolizumab v\u00eda subcut\u00e1nea a dosis est\u00e1ndar tras el cambio de vedolizumab intravenoso, incluso en los pacientes intensificados: resultados de un estudio observacional multic\u00e9ntrico espa\u00f1ol","volume":"48","author":"Andr\u00e9s L.","year":"2025","journal-title":"Gastroenterolog\u00eda y Hepatolog\u00eda"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2025.11525\/2025"},{"key":"e_1_2_11_23_1","first-page":"6","article-title":"Subcutaneous Vedolizumab Treatment in a Real\u2010World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen\u2010Month Prospective Follow\u2010Up Study","volume":"360","author":"Wiken T. H.","year":"2024","journal-title":"Crohns Colitis"},{"key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/ibd\/izad166","article-title":"Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom","volume":"30","author":"Lim S. H.","year":"2024","journal-title":"Inflammatory Bowel Diseases"},{"key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s10620-024-08422-9","article-title":"Real\u2010World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease","volume":"69","author":"Lamichhane N.","year":"2024","journal-title":"Digestive Diseases and Sciences"},{"key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/MEG.0000000000002816","article-title":"Real\u2010Life Experiences of Switching From Intravenous to Subcutaneous Vedolizumab Maintenance Therapy in Patients With Inflammatory Bowel Disease","volume":"36","author":"Kolehmainen S.","year":"2024","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"e_1_2_11_27_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A Simple Index of Crohn's\u2010Disease Activity","volume":"315","author":"Harvey R. F.","year":"1980","journal-title":"Lancet"},{"key":"e_1_2_11_28_1","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis","volume":"14","author":"Lewis J. D.","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.06.026"},{"key":"e_1_2_11_30_1","doi-asserted-by":"crossref","first-page":"175628482412583","DOI":"10.1177\/17562848241258372","article-title":"Long\u2010Term Outcomes and Predictors of Vedolizumab Persistence in Ulcerative Colitis","volume":"17","author":"Gros B.","year":"2024","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"e_1_2_11_31_1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ueg2.12705","article-title":"Effectiveness and Treatment Persistence of Vedolizumab Compared to Anti\u2010Tumour Necrosis Factor\u2010\u03b1 in Patients With Crohn's Disease: A Systematic Literature Review and Meta\u2010Analysis","volume":"13","author":"Armuzzi A.","year":"2025","journal-title":"United European Gastroenterology Journal"},{"key":"e_1_2_11_32_1","doi-asserted-by":"crossref","first-page":"jjaf175","DOI":"10.1093\/ecco-jcc\/jjaf175","article-title":"Switching to Subcutaneous Administration May Offer More Profound Remission Compared to Intensified Intravenous Therapy in Patients With Inflammatory Bowel Disease and Partial Response Following Induction With Intravenous Vedolizumab: The PRIVEDO Study","volume":"19","author":"Macaluso F. S.","year":"2025","journal-title":"Journal of Crohn's & Colitis"},{"key":"e_1_2_11_33_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/apt.15294","article-title":"Three\u2010Year Effectiveness and Safety of Vedolizumab Therapy for Inflammatory Bowel Disease: A Prospective Multi\u2010Centre Cohort Study","volume":"50","author":"Amiot A.","year":"2019","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"e_1_2_11_34_1","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/2050640619873784","article-title":"Early Vedolizumab Trough Levels Predict Treatment Persistence Over the First Year in Inflammatory Bowel Disease","volume":"7","author":"Guidi L.","year":"2019","journal-title":"United European Gastroenterology Journal"},{"key":"e_1_2_11_35_1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/2050640619840211","article-title":"Early Vedolizumab Trough Levels Predict Combined Endoscopic and Clinical Remission in Inflammatory Bowel Disease","volume":"7","author":"Han\u017eel J.","year":"2019","journal-title":"United European Gastroenterology Journal"},{"key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/ecco-jcc\/jjx021","article-title":"Exposure\u2010Efficacy Relationships for Vedolizumab Induction Therapy in Patients With Ulcerative Colitis or Crohn's Disease","volume":"11","author":"Rosario M.","year":"2017","journal-title":"Journal of Crohn's & Colitis"},{"key":"e_1_2_11_37_1","doi-asserted-by":"crossref","first-page":"eadg7549","DOI":"10.1126\/sciimmunol.adg7549","article-title":"Gut\u2010Associated Lymphoid Tissue Attrition Associates With Response to Anti\u2010\u03b14\u03b27 Therapy in Ulcerative Colitis","volume":"9","author":"Canales\u2010Herrerias P.","year":"2024","journal-title":"Science Immunology"},{"key":"e_1_2_11_38_1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/apt.13243","article-title":"Population Pharmacokinetics\u2010Pharmacodynamics of Vedolizumab in Patients With Ulcerative Colitis and Crohn's Disease","volume":"42","author":"Rosario M.","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"e_1_2_11_39_1","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/00365521.2018.1452974","article-title":"A Prospective Cohort Study to Assess the Relevance of Vedolizumab Drug Level Monitoring in IBD Patients","volume":"53","author":"Schulze H.","year":"2018","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"e_1_2_11_40_1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous Infliximab (CT\u2010P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)","volume":"167","author":"Hanauer S. B.","year":"2024","journal-title":"Gastroenterology"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.70986","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/apt.70986","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.70986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:35:14Z","timestamp":1790570114000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.70986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":39,"alternative-id":["10.1111\/apt.70986"],"URL":"https:\/\/doi.org\/10.1111\/apt.70986","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"2026-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"apt.70986"}}